Menu Search
Equities

Haemonetics Corp

HAZ:STU

Haemonetics Corp

Actions
  • Price (EUR)80.50
  • Today's Change1.50 / 1.90%
  • Shares traded0.00
  • 1 Year change+8.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.

  • Revenue in USD (TTM)1.36bn
  • Net income in USD123.81m
  • Incorporated1985
  • Employees3.66k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HAE:NYQ since
announced		Transaction
value
Advanced Cooling Therapy IncDeal completed05 Mar 202405 Mar 2024Deal completed14.44%160.00m
Data delayed at least 15 minutes, as of Nov 22 2024 20:51 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.